Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) - Net Assets
Based on the latest financial reports, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has net assets worth CN¥1.71 Billion CNY (≈ $250.34 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.43 Billion ≈ $355.94 Million USD) and total liabilities (CN¥721.64 Million ≈ $105.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002864 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.71 Billion |
| % of Total Assets | 70.33% |
| Annual Growth Rate | 18.93% |
| 5-Year Change | 109.24% |
| 10-Year Change | 415.24% |
| Growth Volatility | 21.08 |
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Net Assets Trend (2013–2025)
This chart illustrates how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 002864 market cap overview.
Annual Net Assets for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2013–2025)
The table below shows the annual net assets of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2025. Also explore Shaanxi Panlong Pharmaceutical Group Lim (002864) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.69 Billion ≈ $247.16 Million |
+3.17% |
| 2024-12-31 | CN¥1.64 Billion ≈ $239.57 Million |
+5.54% |
| 2023-12-31 | CN¥1.55 Billion ≈ $227.00 Million |
+63.70% |
| 2022-12-31 | CN¥947.60 Million ≈ $138.66 Million |
+17.39% |
| 2021-12-31 | CN¥807.21 Million ≈ $118.12 Million |
+9.73% |
| 2020-12-31 | CN¥735.66 Million ≈ $107.65 Million |
+9.03% |
| 2019-12-31 | CN¥674.71 Million ≈ $98.73 Million |
+10.32% |
| 2018-12-31 | CN¥611.60 Million ≈ $89.50 Million |
+10.08% |
| 2017-12-31 | CN¥555.58 Million ≈ $81.30 Million |
+69.48% |
| 2016-12-31 | CN¥327.82 Million ≈ $47.97 Million |
+13.47% |
| 2015-12-31 | CN¥288.89 Million ≈ $42.27 Million |
+17.34% |
| 2014-12-31 | CN¥246.19 Million ≈ $36.03 Million |
+16.77% |
| 2013-12-31 | CN¥210.84 Million ≈ $30.85 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2323.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥703.10 Million | 41.68% |
| Other Components | CN¥983.74 Million | 58.32% |
| Total Equity | CN¥1.69 Billion | 100.00% |
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Competitors by Market Cap
The table below lists competitors of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
3I Group PLC
LSE:III
|
$319.76 Million |
|
Shenzhen Ruihe Construction Decoration Co Ltd
SHE:002620
|
$319.84 Million |
|
Allot Communications Ltd
TA:ALLT
|
$319.90 Million |
|
Hunan Baili Engineering Sci
SHG:603959
|
$319.99 Million |
|
Materialise NV
NASDAQ:MTLS
|
$319.66 Million |
|
Zhejiang Yangfan New Materials Co Ltd
SHE:300637
|
$319.47 Million |
|
Daeduck Co. Ltd.
KO:008060
|
$319.46 Million |
|
Guangdong Tianhe Agricultural Means
SHE:002999
|
$319.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,635,217,029 to 1,686,834,272, a change of 51,617,243 (3.2%).
- Net income of 96,279,404 contributed positively to equity growth.
- Dividend payments of 43,894,068 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥96.28 Million | +5.71% |
| Dividends Paid | CN¥43.89 Million | -2.6% |
| Other Changes | CN¥-768.09K | -0.05% |
| Total Change | CN¥- | 3.16% |
Book Value vs Market Value Analysis
This analysis compares Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.27x to 1.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.28 | CN¥20.56 | x |
| 2014-12-31 | CN¥3.80 | CN¥20.56 | x |
| 2015-12-31 | CN¥4.46 | CN¥20.56 | x |
| 2016-12-31 | CN¥5.06 | CN¥20.56 | x |
| 2017-12-31 | CN¥8.26 | CN¥20.56 | x |
| 2018-12-31 | CN¥7.09 | CN¥20.56 | x |
| 2019-12-31 | CN¥7.80 | CN¥20.56 | x |
| 2020-12-31 | CN¥8.38 | CN¥20.56 | x |
| 2021-12-31 | CN¥9.26 | CN¥20.56 | x |
| 2022-12-31 | CN¥10.75 | CN¥20.56 | x |
| 2023-12-31 | CN¥15.85 | CN¥20.56 | x |
| 2024-12-31 | CN¥15.64 | CN¥20.56 | x |
| 2025-12-31 | CN¥15.87 | CN¥20.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.71%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.44%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.38x
- Recent ROE (5.71%) is below the historical average (10.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 15.55% | 14.52% | 0.66x | 1.62x | CN¥11.74 Million |
| 2014 | 16.32% | 16.31% | 0.61x | 1.63x | CN¥15.51 Million |
| 2015 | 14.79% | 16.65% | 0.59x | 1.50x | CN¥13.81 Million |
| 2016 | 12.06% | 12.94% | 0.61x | 1.54x | CN¥6.75 Million |
| 2017 | 7.87% | 11.60% | 0.50x | 1.36x | CN¥-11.84 Million |
| 2018 | 10.58% | 13.22% | 0.60x | 1.34x | CN¥3.52 Million |
| 2019 | 10.64% | 11.75% | 0.66x | 1.38x | CN¥4.31 Million |
| 2020 | 10.98% | 11.80% | 0.58x | 1.61x | CN¥7.04 Million |
| 2021 | 11.77% | 10.50% | 0.67x | 1.68x | CN¥14.03 Million |
| 2022 | 10.88% | 10.38% | 0.50x | 2.08x | CN¥8.20 Million |
| 2023 | 7.13% | 11.26% | 0.46x | 1.37x | CN¥-44.47 Million |
| 2024 | 7.36% | 12.35% | 0.43x | 1.39x | CN¥-43.25 Million |
| 2025 | 5.71% | 8.44% | 0.49x | 1.38x | CN¥-72.40 Million |
Industry Comparison
This section compares Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) | CN¥1.71 Billion | 15.55% | 0.42x | $319.75 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more